Hh/Gli antagonist in acute myeloid leukemia with CBFA2T3-GLIS2 fusion gene
Open Access
- 21 January 2017
- journal article
- letter
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-5
Abstract
CBFA2T3-GLIS2 is a fusion gene found in 17% of non-Down syndrome acute megakaryoblastic leukemia (non-DS AMKL, FAB M7) and in 8% of pediatric cytogenetically normal acute myeloid leukemia (CN-AML, in association with several French-American-British (FAB) subtypes). Children with AML harboring this aberration have a poor outcome, regardless of the FAB subtype. This fusion gene drives a peculiar expression pattern and leads to overexpression of some of Hedgehog-related genes. GLI-similar protein 2 (GLIS2) is closely related to the GLI family, the final effectors of classic Hedgehog pathway. These observations lend compelling support to the application of GLI inhibitors in the treatment of AML with the aberration CBFA2T3-GLIS2. GANT61 is, nowadays, the most potent inhibitor of GLI family proteins. We exposed to GANT61 AML cell lines and primary cells positive and negative for CBFA2T3-GLIS2 and analyzed the effect on cellular viability, induction of apoptosis, cell cycle, and expression profile. As compared to AML cells without GLIS2 fusion, GANT61 exposure resulted in higher sensitivity of both cell lines and primary AML cells carrying CBFA2T3-GLIS2 to undergo apoptosis and G1 cell cycle arrest. Remarkably, gene expression studies demonstrated downregulation of GLIS2-specific signature genes in both treated cell lines and primary cells, in comparison with untreated cells. Moreover, chromatin immunoprecipitation analysis revealed direct regulation by GLIS2 chimeric protein of DNMT1 and DNMT3B, two genes implicated in important epigenetic functions. Our findings indicate that the GLI inhibitor GANT61 may be used to specifically target the CBFA2T3-GLIS2 fusion gene in pediatric AML.Keywords
Funding Information
- Fondazione Umberto Veronesi
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Fondazione Città della Speranza (IT)
- PRAT-Università degli studi di Padova
This publication has 10 references indexed in Scilit:
- Recurrent abnormalities can be used for risk group stratification in pediatric AMKL: a retrospective intergroup studyBlood, 2016
- CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemiaOncotarget, 2015
- Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic EffectsClinical Cancer Research, 2015
- Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA bindingOncotarget, 2014
- CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtypeBlood, 2013
- An Inv(16)(p13.3q24.3)-Encoded CBFA2T3-GLIS2 Fusion Protein Defines an Aggressive Subtype of Pediatric Acute Megakaryoblastic LeukemiaCancer Cell, 2012
- Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft modelsJournal of Experimental Medicine, 2012
- Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycinLeukemia Research, 2012
- Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonistsProceedings of the National Academy of Sciences, 2007
- DNA damage response involves modulation of Ku70 and Rb functions by cyclin A1 in leukemia cellsInternational Journal of Cancer, 2007